- |||||||||| Nubeqa (darolutamide) / Bayer, Orion Corp, Erleada (apalutamide) / J&J
Retrospective data, Journal, Real-world evidence, Real-world effectiveness, Real-world, Metastases: Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study. (Pubmed Central) - Mar 25, 2024 The effects of novel ARATs on MFS were consistently observed across subgroups stratified by age (<75 years or ?75 years), history of radical treatment (no or yes), biopsy Gleason score (<9 or ?9), clinical stage (?cT3 and cN0, or cT4 or cN1), and PSADT (?3 months or <3 months). Novel ARATs were significantly associated with improved oncological outcomes in patients with nmCRPC in a real-world setting, regardless of tumor aggressiveness.
- |||||||||| Erleada (apalutamide) / J&J
Enrollment closed, Metastases: Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (clinicaltrials.gov) - Mar 22, 2024 P2, N=102, Active, not recruiting, At present, no SARM has been approved for human consumption; however, SARMs are actually used by bodybuilders and recreational athletes, who purchase them even though the risk-benefit ratio of these molecules has not been definitively established. Recruiting --> Active, not recruiting
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., cyproterone acetate / Generic mfg.
Journal: Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer. (Pubmed Central) - Mar 21, 2024 Moreover, the adaptability of I$^{2}$ADT makes it a promising tool for other cancers with the availability of clinical data, where treatment regimens might need to be individualized based on patient characteristics and disease dynamics. Our research elucidates the application of deep reinforcement learning to identify personalized adaptive cancer therapy.
- |||||||||| abiraterone acetate / Generic mfg.
Review, Journal: Treatment intensification strategies for men undergoing definitive radiotherapy for high-risk prostate cancer. (Pubmed Central) - Mar 20, 2024 Treatment intensification using a combination of EBRT, advanced hormonal therapies, and brachytherapy may improve patient outcomes and survival in men with high-risk prostate cancer. Shared decision-making between patients and multidisciplinary teams of radiation oncologists, urologists, and medical oncologists is essential for personalizing care in this setting and deciding which strategies make sense for individual patients.
- |||||||||| abiraterone acetate / Generic mfg.
Clinical, Journal, Metastases: Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate. (Pubmed Central) - Mar 19, 2024 The association between the use of bone-modifying agents (BMAs) and the outcomes among patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with abiraterone acetate plus prednisone (AAP) remains unclear...Use of BMAs was defined as the administration of bisphosphonates and denosumab within 90 days before and after randomization...Zoledronic acid was the most frequently administered BMA in both the AAP (93 [70.5%]) and the ADT (88 [67.2%]) cohorts...No evidence was found that the outcomes of BMA varied by AAP or ADT (hazard ratio for time to SRE, 0.99 [95% CI, 0.48-2.08]; P?=?.99 for interaction; hazard ratio for OS, 1.31 [95% CI, 0.88-1.96]; P?=?.18 for interaction). The findings of this cohort study suggest that use of BMAs was associated with a longer time to SRE in patients with high-risk mCSPC treated with ADT, with or without AAP, suggesting that BMA use might provide benefits to this population.
- |||||||||| abiraterone acetate / Generic mfg.
Journal: Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer. (Pubmed Central) - Mar 18, 2024 Co-treatment with scalar dilutions of either compound 6 or 6e and the clinically used drug abiraterone led to a significant reduction in cell proliferation, and thus confirmed that treatment with both CYP171A1-and AKR1C3-targeting compounds possess the potential to intervene in key steps in the steroidogenic pathway. Taken together, the novel compounds display desirable biochemical potency and cellular target inhibition as well as good in-vitro ADME properties, which highlight their potential for further preclinical studies.
- |||||||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
No Significant Interactions From Hormone Therapy on F/TAF-Based PrEP in Trans Women: iFACT3 Study (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_600; Intracellular TFV-DP and FTC-TP concentrations in rectal tissue were comparable when F/TAF-based PrEP was administered with and without FHT. These findings align with our previously data in the plasma, urine, and PBMCs compartments, indicating no clinically significant drug-drug interactions from FHT towards F/TAF-based oral daily PrEP are anticipated.
- |||||||||| Nebido (testosterone undecanoate depot injection) / Bayer
Journal, Real-world evidence, Real-world: Testosterone therapy in men with classical versus functional hypogonadism: results from a controlled 9-years, real-world registry study. (Pubmed Central) - Mar 15, 2024 These findings align with our previously data in the plasma, urine, and PBMCs compartments, indicating no clinically significant drug-drug interactions from FHT towards F/TAF-based oral daily PrEP are anticipated. The therapeutic outcomes of TTh across distinct hypogonadal populations demonstrate heterogeneous responses, significantly influenced by diagnostic categorization, age, and baseline risk factor profiles.
- |||||||||| Jatenzo (testosterone undecanoate) / Tolmar
Trial completion date, Trial primary completion date: Testosterone Treatment in Men With Chronic Kidney Disease (clinicaltrials.gov) - Mar 15, 2024 P2, N=20, Recruiting, Not yet recruiting --> Recruiting Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
- |||||||||| Nebido (testosterone undecanoate depot injection) / Bayer
Preclinical, Journal: Intramuscularly injected long-acting testosterone-cholesterol prodrug suspension with three different particle sizes: extended in vitro release and enhanced in vivo safety. (Pubmed Central) - Mar 12, 2024 These findings highlight the potential of dual CYP17A1 and HDAC6 inhibition as a promising strategy for overcoming treatment resistance in GBM and offer new hope for improved therapeutic outcomes. The testosterone undecanoate oil solution is the most widely used injection of testosterone for long-acting effects on the market, whereas the formulation carries the potential risk of causing pulmonary vascular embolism, inflammation, and pain at the injection site...Furthermore, the study on pharmacokinetics exhibited that TST-Chol SNCs produced a sustained TST plasma concentration in vivo for up to 40
- |||||||||| Nubeqa (darolutamide) / Bayer, Orion Corp
Clinical, Journal, HEOR, Real-world evidence, Real-world, Metastases: Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study. (Pubmed Central) - Mar 11, 2024 Regardless of selected therapy regimen, treatment is highly effective and tolerable. Preferably therapy should be administered simultaneously, however if not possible, chemotherapy should be started first.
- |||||||||| enzalutamide capsule / Generic mfg., abiraterone acetate / Generic mfg.
Journal, Metastases: Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide. (Pubmed Central) - Mar 11, 2024 By comparing the rate of hospitalization before vs. during treatment, real world analyses identified a 22% versus 3% increase in hospitalizations with abiraterone compared to enzalutamide respectively, despite being used in a younger population with less comorbid disease. Abiraterone was also associated with higher risk of infections, a novel finding.
- |||||||||| Xofigo (radium Ra-223 dichloride) / Bayer
Review, Journal, Surgery, Metastases: Palliative surgery for metastatic prostate cancer (Pubmed Central) - Mar 7, 2024 In conclusion, Androgen deprivation in combination with novel hormonal agents, docetaxel, or in combination with abiraterone/prednisone plus docetaxel or darolutamid plus docetaxel represent the standard therapeutic approach in metastatic hormone-sensitive prostate cancer (mHSPC)...In addition to systemic chemotherapy, second-line hormonal treatment of systemic application of radionuclides such as radium223 or 177Lu-PSMA represent salvage management options...Complications of the lower urogenital tract such as recurrent gross hematuria
- |||||||||| Nubeqa (darolutamide) / Bayer, Orion Corp
Journal, Metastases: First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer (Pubmed Central) - Mar 7, 2024 Androgen deprivation in combination with novel hormonal agents, docetaxel, or in combination with abiraterone/prednisone plus docetaxel or darolutamid plus docetaxel represent the standard therapeutic approach in metastatic hormone-sensitive prostate cancer (mHSPC)...In addition to systemic chemotherapy, second-line hormonal treatment of systemic application of radionuclides such as radium223 or 177Lu-PSMA represent salvage management options...Complications of the lower urogenital tract such as recurrent gross hematuria Triplet therapy shows a
- |||||||||| Erleada (apalutamide) / J&J
Molecular effects of neo-adjuvant hormone therapy for locally advanced prostate cancer: An ancillary study of the ARNEO phase 2 trial (Section 43) - Mar 5, 2024 - Abstract #AACR2024AACR_9271; P2 In order to understand this better, we ran an ancillary translational study on ARNEO (NCT03080116), a Phase 2 clinical trial, which randomized 89 locally-advanced prostate cancer patients to 12 weeks LHRHa +/- apalutamide (APA) followed by prostatectomy.We performed clinical-grade transcriptome-wide expression array analysis (Veracyte, Inc...We found that expression of STING1 was positively correlated with hallmark interferon alpha response (r=0.7, rs=0.6) that was correlated with apoptosis (r=0.5, rs=0.5).Whilst we show that adding APA to LHRHa increases suppression of AR activity and ERG expression, we find that 12 weeks is insufficient to abrogate AR signaling in most tumors, despite ~98% decrease in serum PSA. We identify novel processes modulated in humans by potent suppression of androgen activity, including upregulation of STING1-type 1 interferon response as a potential key modulator of treatment effect.
|